Immunogenicity Assessment on Clinical Trials of SARS-CoV-2 Vaccines

Various strategies for dealing with COVID-19 have been carried out since the WHO declared as an international health emergency. One of preventive is development vaccines. vaccines developed worldwide. As April 13, 2021, there were 184 vaccine candidates in pre-clinical phase and 16 currently III clinical trials using several platforms, such inactivated viruses, vector protein subunits, mRNA. Clinical SARS-CoV-2 include a screening test consisting thorough physical examination laboratory tests. The safety evaluated based on results referring to standard toxicity grading scale. Immunogenicity assessment at stage includes humoral cellular immunogenicity. immunogenicity measures ability antibodies neutralize virus live neutralization test, Pseudo Virus Neutralization Test (pVNT), Surrogate (sVNT) method. response aims assess immune that leads Th1-cell phenotype. under expected trigger helper 1 (Th1) cell response. Th1-producing Interferon-g (IFNg) formed during acute viral infection, Th1-type correlates milder disease. This one considerations vaccination. phenotype part can be ELISPOT, interferon-gamma release assay, flow cytometry blood samples cultured administration specific peptides. literature review study various assessments